Hepeng Shi, Avistone CEO
December 8, 2021 07:05 AM EST
Financing
China

Vi­vo Cap­i­tal, Bain, Pri­mav­era pour $200M in­to vir­tu­al­ly un­known tar­get­ed on­col­o­gy play out of Chi­na

Amber Tong

Hong­bo Lu was a board mem­ber at Crown­Bio, a pre­clin­i­cal on­col­o­gy CRO, when a lo­cal com­pa­ny — so lo­cal it didn’t even have an Eng­lish name …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times